Peregrine Pharmaceuticals has discovered significant discrepancies while preparing for an end-of-Phase II meeting with regulatory authorities related to data from its Phase II trial of bavituximab in second-line non-small cell lung cancer. The inconsistencies were related to some patient sample test results and patient treatment code assignments, therefore Peregrine was not permitted access to either patient group assignments or related product coding information.   Peregrine had contracted an i...